JASH accepted for coverage in MEDLINE

October 01, 2010

Philadelphia, PA, 1 October, 2010 - Elsevier announces that the Journal of the American Society of Hypertension (JASH) has been selected for inclusion in MEDLINE. MEDLINE is the premier bibliographic database of the U.S. National Library of Medicine (NLM), containing over 15 million journal article citations, with a concentration on biomedicine.

"The entire Editorial Board and I are extremely pleased that JASH has been added to the MEDLINE journal collection," JASH Editor, Myron H. Weinberger, MD, of the Indiana University School of Medicine, commented. "Inclusion in this prominent database signals recognition of the Journal's scientific merit and contribution to the field. But more importantly, MEDLINE indexing will help researchers and other interested parties throughout the world locate articles published in JASH."

As the official journal of the American Society of Hypertension (ASH), the peer-reviewed JASH is circulated to the Society's 2,000+ active members, as well as other subscribers and libraries. JASH publishes peer-reviewed articles on the topics of basic, applied, and translational research on blood pressure, hypertension, and related cardiovascular disorders and factors. JASH strives to provide the tools physicians need to solve everyday problems, while also offering powerful food for thought on the larger issues evolving within the specialty today.

The MEDLINE selection process is managed by an advisory committee, the Literature Selection Technical Review Committee, composed of authorities knowledgeable in biomedicine, who recommend only select journals that the NLM should index. MEDLINE contains bibliographic citations and author abstracts from more than 5,000 biomedical journals published in the United States and 80 other countries, and is searchable for free using PubMed at http://pubmed.gov. Indexing of JASH will include all issues published since its inception in 2007.

With medical practice in a period of rapid change, it is critical for clinicians to understand the regulatory, legal and economic forces that impact their fields, especially a field changing as rapidly as radiology. As publishing partners, the ASH and Elsevier are gratified that researchers and practitioners worldwide can easily find the valuable information offered in JASH now through MEDLINE.
-end-
About the ASH

ASH is the largest US professional organization of scientific investigators and health care professionals committed to eliminating hypertension and its consequences. The Society serves as a scientific forum that bridges current hypertension research with effective clinical treatment strategies for patients. "The mission of the American Society of Hypertension, Inc. (ASH) is to promote strategies to prevent hypertension and to improve the care of patients with hypertension and associated disorders." Membership in ASH includes a subscription to JASH.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Nursing Consult, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Elsevier

Related Hypertension Articles from Brightsurf:

Risk of target organ damage in patients with masked hypertension versus sustained hypertension
In a new publication from Cardiovascular Innovations and Applications; DOI https://doi.org/10.15212/CVIA.2019.1261, Yue Wu, Guoyue Zhang, Rong Hu and Jianlin Du from The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China consider the risk of target organ damage in patients with masked hypertension versus sustained hypertension.

Overactive enzyme causes hereditary hypertension
After more than 40 years, several teams at the MDC and ECRC have now made a breakthrough discovery with the help of two animal models: they have proven that an altered gene encoding the enzyme PDE3A causes an inherited form of high blood pressure.

Diagnosing hypertension in children
Study results call into question the utility of testing blood pressure load--the proportion of elevated blood pressure readings detected over 24 hours--for diagnosing hypertension in children.

When the best treatment for hypertension is to wait
A new study concluded that a physician's decision not to intensify hypertension treatment is often a contextually appropriate choice.

Treatment of hypertension induced albuminuria
Patients with albuminuria will usually need more than one drug to achieve blood pressure control, particularly if the aim is also to reduce albuminuria.

Diagnosing and treating resistant hypertension
Resistant blood pressure affects 12 percent to 15 percent of people currently being treated for high blood pressure.

Dementia can be caused by hypertension
A new study in Cardiovascular Research indicates that patients with high blood pressure are at a higher risk of developing dementia.

Hormone imbalance causes treatment-resistant hypertension
British researchers have discovered a hormone imbalance that explains why it is very difficult to control blood pressure in around 10 per cent of hypertension patients.

Breastfeeding reduces hypertension risk
A study published in the American Journal of Hypertension indicates that women who breastfeed more children, and for longer periods of time, are less likely to suffer from hypertension after they reach menopause.

Lung cancer triggers pulmonary hypertension
Nearly half of all advanced-stage lung cancer patients develop arterial pulmonary hypertension.

Read More: Hypertension News and Hypertension Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.